SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

DiaMedica Therapeutics Inc. (DMAC) News

Follow DiaMedica Therapeutics Inc. (DMAC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol DMAC Asset equity Sector Markets 90 days 3 Last 8.24 Updated Nov 05, 2026, 01:45 PM UTC Open live news feed Open DMAC chart & news
M DiaMedica Therapeutics Schedules Q3 2026 Results and Business Update The company says it will report third-quarter 2026 financial results and provide a business update on November 13, 2026. EQUITY | Nov 05, 2026, 01:45 PM UTC L DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that it w NEWS | Sep 30, 2026, 12:30 PM UTC L DiaMedica management to participate in four September investor conferences DiaMedica Therapeutics management will participate in four upcoming investment bank conferences in September, the company said. EQUITY | Sep 02, 2026, 12:30 PM UTC L DMAC Starts Phase 2 Trial DMAC DiaMedica Therapeutics announces first patients dosed in Phase 2 trial of DM199 for the treatment of fetal growth restriction EQUITY | Jun 23, 2026, 12:32 PM UTC